In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

A novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 m...

Bibliográfalaš dieđut
Váldodahkkit:	Kottaridis, P, Milligan, D, Chopra, R, Chakraverty, R, Chakrabarti, S, Robinson, S, Peggs, K, Verfuerth, S, Pettengell, R, Marsh, J, Schey, S, Mahendra, P, Morgan, G, Hale, G, Waldmann, H, Elvira, d, Williams, C, Devereux, S, Linch, D, Goldstone, A, Mackinnon, S
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2000

Geahča maid

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (2001)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2002)

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2002)

A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (1999)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Dahkki: Hale, G, et al.
Almmustuhtton: (2002)

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
Dahkki: Mackinnon, S, et al.
Almmustuhtton: (1999)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2002)

Excessive T-cell depletion adversely affects transplant-related mortality following allogeneic stem cell transplantation.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2000)

Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2001)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2003)

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
Dahkki: Peggs, K, et al.
Almmustuhtton: (2005)

An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (1999)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2004)

Specificity of monoclonal antibody Campath-1.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Dahkki: Williams, R, et al.
Almmustuhtton: (2000)

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Dahkki: Willis, F, et al.
Almmustuhtton: (2001)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

The CAMPATH-1 antigen (CDw52).
Dahkki: Hale, G, et al.
Almmustuhtton: (1990)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Dahkki: Killick, S, et al.
Almmustuhtton: (1997)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
Dahkki: D'Sa, S, et al.
Almmustuhtton: (2003)

CAMPATH-IH in multiple sclerosis.
Dahkki: Moreau, T, et al.
Almmustuhtton: (1996)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Dahkki: Hale, G, et al.
Almmustuhtton: (1996)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
Dahkki: Friend, P, et al.
Almmustuhtton: (1988)

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
Dahkki: Avivi, I, et al.
Almmustuhtton: (2004)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Dahkki: Mead, A, et al.
Almmustuhtton: (2010)

Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting.
Dahkki: Morgan, G, et al.
Almmustuhtton: (1986)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1987)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Dahkki: Watts, R, et al.
Almmustuhtton: (1992)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Dahkki: Dyer, M, et al.
Almmustuhtton: (1990)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
Dahkki: Buggins, A, et al.
Almmustuhtton: (2001)

Nonmyeloablative allogeneic hematopoietic cell transplantation
Dahkki: Rainer Storb, et al.
Almmustuhtton: (2016-05-01)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Dahkki: Novitzky, N, et al.
Almmustuhtton: (2004)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
Dahkki: Xia, M, et al.
Almmustuhtton: (1993)